Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | -.--% | -.--% |
Mar. 22 | Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. | CI |
Mar. 04 | Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. | CI |
Financials (USD)
Sales 2021 | 4.21M | Sales 2022 | 12.69M | Capitalization | 165M |
---|---|---|---|---|---|
Net income 2021 | -65M | Net income 2022 | -75M | EV / Sales 2021 | 168 x |
Net cash position 2021 | 148M | Net cash position 2022 | 21.66M | EV / Sales 2022 | 11.3 x |
P/E ratio 2021 |
-10.8
x | P/E ratio 2022 |
-2.17
x | Employees | 200 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 87.9% |
1 day | -99.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Maria Sullivan
CTO | Chief Tech/Sci/R&D Officer | - | - |
Yuri Maricich
CTO | Chief Tech/Sci/R&D Officer | 44 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 69 | 21-11-30 | |
Timothy A. Wicks
BRD | Director/Board Member | 58 | 22-06-13 |
Corey McCann
BRD | Director/Board Member | 45 | 21-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 18 M€ | +2.79% | - |
1st Jan change | Capi. | |
---|---|---|
-.--% | 142 | |
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
-4.07% | 11.68B | |
+21.36% | 11.6B | |
+8.20% | 11.15B |
- Stock Market
- Equities
- PEAR.Q Stock